Metabolic

AOD 9604

Peptide fragment · GH C-terminus (176–191) · Synthetic

FDA · CATEGORY 2 (2023)

Half-life

~22 minutes

Very short

minsdays

Route

SubQ injection

Evidence

Early human data

Risk

Standard

Overview

Known for

Modified fragment of HGH (amino acids 176-191). Specifically targets fat metabolism without the growth-promoting effects of full HGH. Stimulates lipolysis and inhibits lipogenesis.

Mechanism

Modified HGH fragment (aa 177-191). Proposed to stimulate lipolysis without HGH's growth/diabetogenic effects. Evidence very weak.

Key facts

Format
Lyophilized powder
Mechanism targets
Classification
Secondary
Supply & nature
Natural / Topping UpNatural
FDA category
Category 2 (2023)

Evidence & standing

Evidence base
Early human data
Risk level
Standard
Best studies
4 references
  • Heffernan et al. (2001) Obes Res 9(3):179-86 — GH fragment lipolysis in rodents
  • Stier et al. (2013) — Cartilage regeneration properties
  • FDA GRAS status granted for food use (2015), NOT FDA APPROVED as injectable therapeutic
  • Limited human clinical data available

Dosage & protocol

Typical dose
250-500mcg/day
Research range
250–300 µg
Cycle
Daily, pre-fasted
Onset
35 days first effects
Full effect
98 days
Half-life
~15-30min
~15-30 minutes (very short)
Protocol

250-500mcg/day SubQ. Some protocols use 300mcg morning fasted.

Time to effects

EARLY: 4-6 weeks

FULL: 12-16 weeks

AOD works subtly — don't expect the dramatic appetite suppression of GLP-1 agonists.

Week 2-4: No obvious changes. Working at cellular level on fat metabolism.

Week 4-8: Mild reduction in stubborn fat areas may begin. Improved body composition.

Week 12-16: Cumulative fat loss becomes noticeable, especially in abdominal area.

Minimum commitment: 8-12 weeks. Results are modest compared to GLP-1 agonists. Best as part of a stack, not standalone.

Recommended vial
  • 5mg vials

At 300mcg/day, 5mg = ~17 days ✓. 2mg = 7 days (wasteful). 10mg = 33 days (borderline but OK).

Reference figures only

Dosing reflects published laboratory protocols and is not guidance for use in any living subject.

Safety

Reversibility
Fully Reversible
Side effects

Injection site irritation, headache (reported). Limited safety data from human trials.

Interactions

No significant known interactions (limited data)

Handle with research caution

No strict contraindications with other peptides on this list.

Storage & handling

Lyophilised
12–24 months
room temp
Reconstituted
4–6 weeks
2–8°C

Videos & talks

Independent educational content from researchers, clinicians and science communicators — not affiliated with Pepnerd.

Educational resources only. Videos are independent third-party content. Pepnerd is not affiliated with these creators and does not endorse or make claims based on their content. All products are for in-vitro research.